Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2014-001357-17-CZ
EUCTR2014-001357-17-CZActive, not recruitingPhase 1

An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV Study - CONTINUATION-PV

AOP Orphan Pharmaceuticals AG0 sites200 target enrollmentStarted: October 8, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
200
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Patients who completed PROUD-PV Study.
  • •a. normalization of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were moderately increased (Hct<50%, WBC<20 x 10^9/L, PLTs<600 x 10^9/L) at baseline of the PROUD-PV Study, OR
  • •b. >35% decrease of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were massively increased (Hct>50%, WBCs>20 x 10^9/L, PLTs>600 x 10^9/L), at baseline of the PROUD-PV Study, OR
  • •c. normalization of spleen size, if spleen was enlarged at baseline of the PROUD-PV Study, OR
  • •d. otherwise a clear, medically verified benefit from treatment (e.g. normalization of disease-related micro-vasculatory symptoms, substantial decrease of JAK2 allelic burden).
  • •2. Signed written ICF.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 140
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 60

Exclusion Criteria

  • •Withdrawal criteria, as specified in the PROUD-PV (and PEN-PV) study, which mandate treatment discontinuation:
  • •1. Non-recovery from the treatment related toxicities to the grade (usually, grade I) which allows continuation of the treatment.
  • •2. HADS score of 11 or higher on either or both of the subscales, and/or development or worsening of the clinically significant depression or suicidal thoughts.
  • •3. Progressive and clinically significant increase of liver enzyme levels despite dose reduction, or if such increase is accompanied by increased bilirubin level or any signs or symptoms of a clinically significant autoimmune disease.
  • •4. Clinically significant development of a new ophthalmologic disorder, or worsening of a pre-existing one, during the study.
  • •5. AOP2014 arm only: Loss of efficacy of study treatment or any comparable situation where no further benefits of treatment continuation are expected by the investigator.
  • •Sub-study 2: Evaluation of PK of AOP2014 with the 250 µg pen (0.5 mg/ml) and 500 µg pen (1 mg/ml) within the CONTINUATION-PV Study
  • •a)AOP2014 PK characterisation in steady state (PK group 1 and 2)
  • •For the estimation of the systemic exposure of AOP2014, blood samples will be collected in the dosing interval between two AOP2014 administrations (i.e. 2-weekly and 4-weekly). Patients within the CONTINUATION-PV Study are eligible for blood sampling who
  • •are treated with AOP2014 with the pre-filled pen (250 µg or 500 µg pen; applicable for all dose levels), and
  • •are receiving AOP2014 in a 2-weekly (PK group 1) or 4-weekly interval (PK group 2), and
  • •having received at least 4 stable and consecutive (no dose interruption within 2 months prior entry in sub-study) AOP2014 doses with the same
  • •type of pen (250 µg or 500 µg) and
  • •are giving consent.
  • •b)Estimation of the AOP2014 terminal elimination half-life (PK group 3)
  • •Patients within the CONTINUATION-PV Study are eligible for blood sampling at the last AOP2014 administration until elimination to unquantifiable levels who
  • •have a temporally interruption of the AOP2014 treatment long enough to participate in the PK sub-study (up to 56 days [+/- 2 days])
  • •do not directly continue with AOP2014 (or another interferon) therapy after study end, or
  • •drop-out from the study due to reasons not related to safety and who decided to not continue with AOP2014/IFN therapy, or
  • •drop-out from the study due to safety reasons where the treating physician decided that blood sampling is feasible and where the patients
  • •decided to not continue with AOP2014/interferon therapy, and
  • •are giving consent.

Investigators

Similar Trials

Active, not recruiting
Phase 1
An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV StudyPolycythemia Vera
EUCTR2014-001357-17-BGAOP Orphan Pharmaceuticals AG200
Active, not recruiting
Phase 1
An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 in patients with Polycythemia Vera who previously participated in the PROUD-PV studyMedDRA version: 17.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864Polycythemia Vera
EUCTR2014-001357-17-ESAOP Orphan Pharmaceuticals AG130
Active, not recruiting
Phase 1
An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV StudyMedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864Polycythemia Vera
EUCTR2014-001357-17-ATAOP Orphan Pharmaceuticals AG200
Active, not recruiting
Phase 1
An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT)in patients with Polycythemia Vera who previously participated in the PROUD-PV StudyMedDRA version: 20.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864Polycythemia Vera
EUCTR2014-001357-17-HUAOP Orphan Pharmaceuticals AG200
Active, not recruiting
Phase 1
An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV StudyMedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864Polycythemia Vera
EUCTR2014-001357-17-SKAOP Orphan Pharmaceuticals AG200